论文部分内容阅读
目的 :探讨舒喘方合沙美特罗替卡松吸入剂治疗儿童支气管哮喘缓解期的临床疗效。方法 :将108例患儿随机分为3组,中药组36例采用舒喘方口服治疗,西药组36例采用沙美特罗替卡松吸入剂治疗,中西医治疗组36例予舒喘方口服联合沙美特罗替卡松吸入剂治疗。疗程均为9月,以呼气峰流速值变化来评价临床疗效,并统计随访3月的复发率。结果:总有效率中西医治疗组为94.4%,西药组为83.3%,中药组为55.6%;中西医治疗组、西药组显著高于中药组(P<0.05);中西医治疗组与西药组比较,差异无统计学意义(P>0.05)。喘息复发率中西医治疗组为16.7%,西药组为27.8%,中药组为75.0%;中西医治疗组、西药组均较中药组低(P<0.05);中西医治疗组与西药组比较,差异无统计学意义(P>0.05)。结论:舒喘方联合沙美特罗替卡松吸入剂治疗儿童支气管哮喘缓解期可提高临床疗效,减少复发,值得临床推广应用。
Objective: To investigate the clinical effect of Shuchuanfosartrate and Trospixon for the treatment of childhood bronchial asthma in remission. Methods: 108 cases were randomly divided into three groups. 36 cases in the traditional Chinese medicine group were treated with Shuchuan decoction, 36 cases in the western medicine group were treated with salmeterol and tiaducin inhalation, 36 cases in the traditional Chinese and western medicine group were given Shuchuan decoction Combined salmeterol and fluticasone inhaler therapy. The course of treatment was September. The clinical efficacy was evaluated by the change of peak expiratory flow rate, and the recurrence rate was followed up in March. Results: The total effective rate was 94.4% in traditional Chinese and western medicine group, 83.3% in western medicine group and 55.6% in traditional Chinese medicine group, significantly higher in traditional Chinese and western medicine group and western medicine group than in traditional Chinese medicine group (P <0.05) The difference was not statistically significant (P> 0.05). The wheezing recurrence rate was 16.7% in the Western medicine group, 27.8% in the western medicine group and 75.0% in the traditional Chinese medicine group, and lower in the Western medicine group and western medicine group (P <0.05). Compared with western medicine group, The difference was not statistically significant (P> 0.05). Conclusion: Shuchuan decoction combined with salmeterol and fluticasone may improve the clinical curative effect and reduce the recurrence in children with bronchial asthma. It is worthy of clinical application.